Integrin αV and β5 partner to drive cancer cell growth
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
List view / Grid view
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
Learn how scientists like you are using Namocell single cell sorters through summaries of seven recent peer-reviewed citations.
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
Using CRISPRa to activate genes in readily accessible cells provides an effective and accurate diagnosis of genetic diseases.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
Researchers have made surprising and important findings that may influence organoid and cell reprogramming studies.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
Tips and tricks for fully leveraging Advanced Flow Cytometry.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Findings of rare CRISPR-linked gene modules and a novel CRISPR-Cas system have promising implications for genomic therapeutics.
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
CRISPR-DREAM tool used to activate insufficiently expressed genes and convert skin cells to induced pluripotent stem cells (iPSCs).
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
In Columbus, Ohio, scientists have made significant strides in developing vaccines to combat leishmaniasis, a disfiguring skin disease, through animal studies.
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.